Vanguard Investments Australia
PRME icon

Vanguard Investments Australia’s Prime Medicine PRME Stock Holding History

Vanguard Investments Australia’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$96.4K Hold
26,124
– – ﹤0.01% 2310
2026
Q1 		$90.9K Buy
+26,124
New +$99.4K ﹤0.01% 2294

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Investments Australia's PRME Position: Q2 2026 in Review

Vanguard Investments Australia held its Prime Medicine (PRME) position steady in Q2 2026 at 26,124 shares worth $96.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2310.

Vanguard Investments Australia first reported a position in PRME in Q1 2026 and has held it in 2 quarters since. 174 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Vanguard Investments Australia held 26,124 shares of Prime Medicine worth $96.4K as of Q2 2026.
  • Vanguard Investments Australia left its Prime Medicine share count unchanged in Q2 2026.
  • Prime Medicine made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #2310 holding.
  • Vanguard Investments Australia first reported a position in Prime Medicine in Q1 2026 and has held it in 2 quarters since.
  • 174 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.